Tele-monitored tDCS rehabilitation: feasibility, challenges and future perspectives in Parkinson's disease.
Alberto Cucca, Kush Sharma, Shashank Agarwal and 2 others
PMID 30704491WHAT IT FOUND
Remote tDCS for Parkinson's is feasible and safe, with high compliance and mild side effects.
Efficacy data is pending or limited to small open-label studies, so it should not be used as a proven treatment for motor or cognitive symptoms yet.
Key findings
01Remotely supervised tDCS in Parkinson's patients showed high compliance and safety, with adverse events similar to lab-based tDCS.
02A small open-label study reported significant improvements in motor scores, particularly axial/balance symptoms, but lacked a control group.
03Efficacy for fatigue and cognitive slowing remains unproven as data from the ongoing double-blind pilot trial is still pending.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The review is narrative, not systematic, and relies heavily on small, open-label, or pilot studies. The positive motor findings come from an uncontrolled study, making it impossible to rule out placebo effects or natural variation. Most included studies had small sample sizes (e.g., 6 to 16 participants), limiting generalizability. The long-term effects and efficacy for key PD symptoms like fatigue and cognition remain unknown.
Declared interests
The study was funded by the National Parkinson Foundation. No other specific conflicts of interest are declared in the provided text.
The easy way to misread this
Do not interpret the reported improvements in motor scores as proof that tele-tDCS is an effective treatment for Parkinson's. These findings come from small, open-label studies without a control group, meaning the benefits could be due to placebo effects or concurrent cognitive training, and efficacy data from controlled trials is still pending.